Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.87 |
| ▸ | BRD4 | O60885 | 6/20 | 0.75 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.71 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.69 |
| ▸ | BRD2 | P25440 | 1/20 | 0.66 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6943872 | 0.93 | MAPK14 (1.00) | MAPK14BRD4MAPK11BRDT | |
| Trifluoroacetic Acid SCHEMBL6951253 | 0.90 | MAPK14 (0.88) | MAPK14BRD4MAPK11BRDT | |
| Trifluoroacetic Acid SCHEMBL6948135 | 0.90 | MAPK14 (0.87) | MAPK14BRD4BRDT | |
| Trifluoroacetic Acid SCHEMBL6950915 | 0.89 | MAPK14 (0.86) | MAPK14BRD4BRDT | |
| SCHEMBL7815820 | 0.89 | MAPK14 (0.91) | MAPK14BRD4MAPK11BRDT | |
| SCHEMBL3300552 | 0.88 | MAPK14 (1.00) | MAPK14BRD4MAPK11BRDT | |
| Trifluoroacetic Acid SCHEMBL6949238 | 0.85 | MAPK14 (0.69) | MAPK14BRD4MAPK11BRDT | |
| SCHEMBL6950475 | 0.85 | MAPK14 (1.00) | MAPK14BRD4MAPK11BRDT | |
| SCHEMBL6955254 | 0.85 | MAPK14 (0.81) | MAPK14BRD4MAPK11BRDT | |
| SCHEMBL6948107 | 0.83 | MAPK14 (1.00) | MAPK14BRD4MAPK11BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0996446-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6562832-B1 | Cytokine suppressive anti-inflammatory drugs, capable of inhibiting the CSBP/p38/RK kinase | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| US-6046208-A | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, ENDOTOXEMIA AND/OR TOXIC SHOCK SYNDROME, OTHER ACUTE OR CHRONIC INFLAMMATORY DISEASE STATES SUCH AS THE INFLAMMATORY REACTION INDUCED BY ENDOTOXIN OR INFLAMMATORY BOWEL DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |